InsiderSignal.AI

InsiderSignal.ai

KNSA - Kiniksa Pharmaceuticals International, Plc

Insider Sale by Moat Ross (COO)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

5 days ago, Moat Ross, serving as COO at Kiniksa Pharmaceuticals International, Plc (KNSA), sold 1,703 shares at $46.69 per share, for a total transaction value of $79,513.00. Following this transaction, Moat Ross now holds 12,029 shares of KNSA.

This sale represents a 12.00% decrease in Moat Ross's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Thursday, April 9, 2026 and publicly disclosed via SEC Form 4 filing on Monday, April 13, 2026, 4 days after the trade was made.

Kiniksa Pharmaceuticals International, Plc operates in the HEALTHCARE sector, specifically within the DRUG MANUFACTURERS - SPECIALTY & GENERIC industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Moat Ross

Moat Ross

COO

Ross Moat is the Executive Vice President and Chief Operating Officer at Kiniksa Pharmaceuticals International, Plc (KNSA), a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapies for unmet medical needs.[[1]](https://www.kiniksa.com/leadership)[[2]](https://www.gurufocus.com/news/8782905/insider-selling-ross-moat-sells-shares-of-kiniksa-pharmaceuticals-international-plc) He joined Kiniksa in 2019, bringing over 30 years of experience in the biopharmaceutical industry, with expertise in scientific, clinical, and commercial operations, particularly in orphan and ultra-orphan diseases.[[1]](https://www.kiniksa.com/leadership) Moat's career highlights include leading the commercialization of innovative gene therapies at Novartis Gene Therapies and Spark Therapeutics, serving as metabolic franchise commercial head at Alexion after acquiring Synageva (where he was General Manager, UK & Ireland), and earlier roles at Genzyme—where he led the Fabrazyme® clinical program to FDA approval in 2003—and at Burroughs Wellcome, Hoechst Marion Roussel, and Fujisawa/Otsuka.[[1]](https://www.kiniksa.com/leadership) He holds a first-class BA (Honors) in Business Management from Middlesex University Business School in London.[[1]](https://www.kiniksa.com/leadership) Recently, as COO, Moat sold 2,367 shares of KNSA on April 6, 2026, retaining 13,732 shares.[[2]](https://www.gurufocus.com/news/8782905/insider-selling-ross-moat-sells-shares-of-kiniksa-pharmaceuticals-international-plc)

View full insider profile →

Trade Price

$46.69

Quantity

1,703

Total Value

$79,513.00

Shares Owned

12,029

Trade Date

Thursday, April 9, 2026

5 days ago

SEC Filing Date

Monday, April 13, 2026

Filed 4 days after trade

HEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC

About Kiniksa Pharmaceuticals International, Plc

Company Overview

No company information available
View news mentioning KNSA

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/5612874

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime